Imagine a world where diagnosing diseases is as simple as a quick saliva test. That future is getting closer, thanks to a groundbreaking agreement between the International Iberian Nanotechnology Laboratory (INL), the University of Minho (UMinho), and IPLEXMED, a company specializing in advanced medical diagnostics. They've joined forces to bring a revolutionary graphene-based diagnostic platform to market.
This isn't just another scientific breakthrough; it's a game-changer. The core of this technology, developed through the MULTIMAL project and patented in 2024 with support from HORIZON 2020, lies in its use of monolayer graphene field-effect transistor (FET) sensors. These tiny sensors are incredibly sensitive, designed to detect diseases like malaria and others with remarkable precision.
But here's where it gets exciting: this platform can analyze samples of saliva or urine. Forget invasive procedures; this technology promises non-invasive, rapid, and highly sensitive detection. The sensors are so sensitive, they can detect substances at the attomolar level!
INL leadership highlights this as a pivotal moment, a transition from lab research to real-world applications. This collaboration proves the tangible impact of advanced materials.
What do you think about the potential of this technology? Do you believe this will change the future of healthcare? Share your thoughts below!
